Commentary: Review compromises cancer drug development

05/29/2008 | Wall Street Journal (free content), The

A decision by Sen. Charles Grassley, R-Iowa, will have a disastrous effect on the U.S. cancer drug pipeline, Dr. Mark Thornton writes in The Wall Street Journal. Grassley has asked the Government Accountability Office to investigate the FDA's fast-track approval of Avastin, a breast cancer drug, and the agency's use of "surrogate endpoints" in regulatory approvals. The senator's demand for a complete review of every FDA-approved drug undermines the agency's authority in ensuring product safety and comes at a time when the development of new products "is longer and costlier than the last," writes Thornton, a former medical officer at the FDA's Office of Oncology Products.

View Full Article in:

Wall Street Journal (free content), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations